Practical examples of advanced practice provider–led initiatives that improve safety, symptom management, and patient ...

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk ...

Emese Zsiros, MD, PhD, FACOG, discusses managing paclitaxel toxicity and the role of pembrolizumab maintenance in treating platinum-resistant ovarian cancer. Following the FDA’s approval of ...

Rinatabart sesutecan (Rina-S) demonstrated a 100% disease control rate at the 100-mg/m 2 dose for patients with heavily ...

Jakel shared the story of a young mother who had been deemed difficult and “in denial” by other staff due to her rejecting ...

Optune Pax plus gemcitabine/nab-paclitaxel improved OS in ITT LA-PAC patients (16.2 vs 14.2 months; HR 0.82; P=.039) with higher 1-year survival. Modified per ...

The advantage of MCED testing is its potential to identify cancers at earlier, more treatable stages; detecting cancer even ...

An advocate is not the same as a health care proxy who is assigned to speak for a patient on their advanced directives.

RMAT status for KB707 enables expedited development with enhanced FDA engagement, supported by early KYANITE-1 activity and durability in heavily pretreated advanced/metastatic NSCLC. LungTIME-C01 ...

David C. Leopold, MD, explains how evidence-based integrative therapies like acupuncture and nutrition improve oncology patient outcomes and compliance. Integrative therapies such as acupuncture, ...